跳到正文
原文
Medical Xpress·· 1 天前精选AI 评分75

针对 Down 综合征的免疫过度活跃显示二期临床试验前景

Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

AI 导读

一项针对 Down 综合征免疫过度活跃的二期临床试验显示,托法替尼可减少炎症并改善皮肤状况。研究还发现该药物可调节特定炎症途径而不完全抑制免疫反应,为未来治疗提供新方向。

推荐理由

研究显示托法替尼可减少炎症并改善皮肤状况,为未来针对 Down 综合征的治疗提供新方向。

正文
New treatment targeting immune overactivity in Down syndrome patients shows promise in phase 2 clinical trial
Credit: Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.103138

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and Alzheimer's disease.

The phase 2 clinical trial of tofacitinib, a medication known as a JAK inhibitor that blocks certain signals involved in immune responses and inflammation, was published in Cell Reports Medicine.

The findings provide important evidence that targeting underlying immune dysregulation may offer a new approach to addressing multiple health conditions associated with Down syndrome.

Why researchers targeted immune hyperactivity in Down syndrome

Down syndrome is caused by an extra copy of chromosome 21, which carries genes encoding several receptors for interferons, molecules that regulate immune responses. Previous research by the Crnic Institute established that this genetic change contributes to chronically elevated interferon signaling and widespread immune dysregulation. The new study tested whether reducing this excessive signaling could be a viable therapeutic approach.

How the phase 2 clinical trial for JAK inhibition worked

The research team enrolled adolescents and adults with Down syndrome who also had inflammatory skin conditions, such as hidradenitis suppurativa and alopecia areata. Participants received tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks. The trial included extensive safety monitoring, dermatological evaluations, blood-based molecular analyses and neuropsychological assessments. The study also evaluated changes in biological markers associated with brain health and Alzheimer's disease.

"This study represents an important milestone in our efforts to develop new treatments for people with Down syndrome," said Joaquín Espinosa, executive director of the Crnic Institute, professor of pharmacology and senior author of the study. "We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions. The results of this study lay the groundwork for future clinical trials that could address a broader range of conditions associated with Down syndrome."

Study finds reduced inflammation and improvements in skin conditions

The study met its predefined safety endpoint, with a safety profile similar to that observed in the general population. The findings do not eliminate the known risks of JAK inhibitors, and larger studies will be needed to assess long-term safety in Down syndrome.

Blood analyses showed significant reductions in interferon activity, inflammatory cytokine scores and metabolites associated with inflammation, including quinolinic acid, a compound with known neurotoxic effects. Extensive analyses of gene expression, circulating proteins and metabolites showed that tofacitinib modified specific inflammatory pathways rather than completely shutting down immune responses.

"One of the most exciting findings is that we could bring several abnormal inflammatory markers closer to the levels observed in people without Down syndrome," said Angela Rachubinski, first author of the study. "Importantly, this medication appears to calm an overactive immune system without weakening normal immune defenses in people with Down syndrome, which may explain its encouraging safety profile."

Participants also showed improvements in inflammatory skin conditions, particularly hidradenitis suppurativa, which causes painful skin lesions, and alopecia areata, an autoimmune condition that causes hair loss. Improvements were documented through standardized clinical scores and measures of dermatology-related quality of life.

Neurobehavioral findings are promising but preliminary

The investigators additionally observed improved performance on selected tests of attention, memory, vocabulary and behaviors, along with favorable changes in some participant- and caregiver-reported measures of well-being. These findings are preliminary: because the study had no placebo comparison group, researchers cannot determine whether the observed changes were caused by tofacitinib rather than practice effects or other factors.

"The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition," said Lina Patel, a study co-author and professor of psychiatry at CU Anschutz. "What this study establishes is an opportunity to ask more precise questions about which improvements may be due to treatment, while continuing to prioritize participant safety."

These findings may help advance research into how chronic immune overactivity affects the brain and whether targeting inflammation could improve brain health in people with Down syndrome. Researchers documented favorable changes in several biomarkers related to neurological function and Alzheimer's disease, opening new avenues of future research.

Based on the results from this first trial, researchers launched a second trial focused on Down syndrome regression disorder, a condition characterized by sudden loss of neurological function that has been associated with inflammatory processes affecting the brain. Results from this second trial are expected to be available in 2027.

The research builds on the Crnic Institute's Human Trisome Project, which has mapped immune and molecular changes associated with Down syndrome. By comparing trial findings with those earlier datasets, the team identified biological changes that may be responsive to JAK inhibition and biomarkers for monitoring treatment effects.

"As the mother of my amazing 23-year-old daughter Sophia, it is deeply moving to see the Crnic Institute's groundbreaking research, which GLOBAL supported from the beginning, lead to promising clinical results," said Michelle Sie Whitten, president and CEO of the Global Down Syndrome Foundation. "We are grateful to the NIH INCLUDE Project and to Espinosa and his team for focusing on scientific discoveries leading to longer, healthier lives."

What the findings mean for future Down syndrome treatments

The authors emphasize that tofacitinib is not approved specifically for Down syndrome and that the study does not establish a general treatment recommendation. The findings support further randomized, placebo-controlled studies to evaluate clinical benefits, optimal participant selection and longer-term safety.

Publication details

Angela L. Rachubinski et al., A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome, Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.103138

Journal information: Cell Reports Medicine

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clinical.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com